CPA1 and breast carcinoma: More specifically, in luminal subtype breast cancer samples, the mean percentage of methylated CpC, CpT, CpG and CpA sites was 82.91 ± 3.09%, 81.39 ± 4.50%, 89.22 ± 3.59%, and 76.61 ± 2.68%, respectively; however, in TNBC samples, the mean percentage of methylated CpC, CpT, CpG and CpA sites were 19.16 ± 11.10%, 18.80 ± 15.06%, 23.06 ± 10.88%, and 20.94 ± 10.49%, respectively (Figs. 3b–e).